first-line parp inhibitor maintenance therapy in advanced

Upload: others

Post on 24-Jan-2022

6 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Page 1: First-line PARP Inhibitor Maintenance Therapy in Advanced

Discussion

Bringing the evidence together:efficacy, safety, and quality of life

Introduction to PARPi maintenance therapy

Individualizing patient care during PARPi maintenance therapy

Bradley J. Monk

Faculty

Antonio González Martín

Alexandra Leary

Topic Presenter

Programme

Tuesday, 21 September 2021, 17:35-19:05 CEST, Channel 5

Bradley J. Monk St. Joseph's Hospital and Medical CenterPhoenix, AZ, USA

Antonio González MartínCancer Center

Universidad de NavarraNavarra, Spain

Alexandra Leary (Chair)Gustave Roussy Cancer Center

Paris, France

First-line PARP Inhibitor Maintenance Therapy in Advanced Ovarian Cancer: Improving Safety Outcomes and the Patient Experience

ESMO 2021 Industry Satellite Symposium

Nephroprotection: Actual perspective of ACE inhibitor therapy Piero Ruggenenti

Signal Transduction Guide - Website editionSignal Transduction Product Guide Potent PARP inhibitor, NU 1025 NU 1025 (Cat. No. 1401) is a potent inhibitor of the DNA repair enzyme poly(ADP-ribose)

Antiinfective therapy with a small molecule inhibitor of ... · Antiinfective therapy with a small molecule inhibitor of Staphylococcus aureus sortase Jie Zhanga,1, Hongchuan Liua,1,

Alpha 1 – Antitrypsin Inhibitor Therapy Medication ......Alpha 1 – Antitrypsin Inhibitor Therapy Medication Precertification Request . Page 2 of 2 (All fields must be completed

P2Y12 inhibitor monotherapy or dual antiplatelet therapy

Signal Transduction Guide - Website edition...Signal Transduction Product Guide Potent PARP inhibitor, NU 1025 NU 1025 (Cat. No. 1401) is a potent inhibitor of the DNA repair enzyme

Evidence-Based Medicine ACE-Inhibitor and ARB; combination therapy

Www.OncologyEducation.ca Efficacy of BSI-201, a PARP-Inhibitor in combination with Gemcitabine/Carboplatin in Triple Negative Breast Cancer: Randomized

TALAZOPARIB (PARP INHIBITOR) IN BREAST CANCER · PDF filepizer in all right reerve ay talazoparib talazoparib (parp inhibitor) in breast cancer talazoparib as a dual-mechanism parp

Date1 PARP Inhibition: A New Approach To Cancer Therapy? Dr. Geert Kolvenbag

Salvage pembrolizumab added to kinase inhibitor therapy

Selective resistance to the PARP inhibitor olaparib in a ... · Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer

The Chk1 Inhibitor, SRA737, Synergizes with the PARP ...filecache.investorroom.com/mr5ircnw_sierra/165/Sierra_AACR_SRA737 niraparib_FINAL.pdfsiSCR siCD95siFADD siAIF siBAK siBAX siBAD

Tyrosine Kinase Inhibitor Therapy for Brain Metastases in

Step Therapy Requirements - Connecture€¦ · prior claim for an angiotensin converting enzyme inhibitor (ace inhibitor), or ace inhibitor combination or a generic angiotensin receptor

Human mass balance study and metabolite profiling …...Human mass balance study and metabolite profiling of14C-niraparib,anovelpoly(ADP-Ribose)polymerase(PARP)-1 and PARP-2 inhibitor,

Ten-day high-dose proton pump inhibitor triple therapy

Efficacy and safety of tau-aggregation inhibitor therapy

PD-1 Inhibitor Therapy S - ONS

FGF1p38 MAP kinase inhibitor therapy induces cardiomyocyte ... · FGF1p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after

Efficacy of PARP inhibitor rucaparib in orthotopic glioblastoma ...mct.aacrjournals.org/content/molcanther/early/2015/10/02/1535-7163... · Efficacy of PARP inhibitor rucaparib in

RAD51 Mediates Resistance of Cancer Stem Cells to PARP ......Cancer Therapy: Preclinical RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast

Effective use of PI3K inhibitor BKM120 and PARP inhibitor

TALAZOPARIB (PARP INHIBITOR) IN BREAST CANCER · 2020-05-02 · Pizer In All Right Reerve ay Talazoparib TALAZOPARIB (PARP INHIBITOR) IN BREAST CANCER TALAZOPARIB AS A DUAL-MECHANISM

Front-line Therapy of DIPG Using IDO Pathway Inhibitor

Effect of Tumor Necrosis Factor Inhibitor Therapy on ...downloads.hindawi.com/journals/bmri/2017/2690402.pdf · ResearchArticle Effect of Tumor Necrosis Factor Inhibitor Therapy on

Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 … · Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors Janneke E. Jaspers 1,2 , Ariena

TALAZOPARIB (PARP INHIBITOR) IN BREAST CANCERMurai J, Huang SYN, Renaud A, et al. Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib. Mol Cancer Ther

SOLO-1€¦ · SOLO-1 is the first Phase III trial to investigate maintenance therapy with a PARP inhibitor in newly diagnosed ovarian cancer *Upfront or interval attempt at optimal

MSH3MediatesSensitizationofColorectalCancerCellsto ...Olaparib, a PARP inhibitor, was purchased from Selleck Chemicals (Houston, TX). Cell Lines and Cell Culture—The human colon

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib

ALDH1A1 contributes to PARP inhibitor resistance via · 2019. 9. 18. · d treated with . various doses of. PARPi . or . the . ALDH1A1 inhibitor. for 7 days. C. ells were . then washed

PARP Inhibition: A New Approach To Cancer Therapy? Dr. Geert Kolvenbag

Rational combination therapy with PARP and MEK inhibitors ...stm.sciencemag.org/content/scitransmed/9/392/eaal5148.full.pdf · Rational combination therapy with PARP and MEK inhibitors

Combination Therapy of NSCLC Using Hsp90 Inhibitor …nanotheranosticlab.com/pubs/25. Molecular Pharmaceutics NC.pdfCombination Therapy of NSCLC Using Hsp90 Inhibitor and Doxorubicin